Free Biopharma Investor Posts

Private bio/pharma funding activity rose sharply in Q3 2026 after a difficult first half. BiopharmIQ recorded approximately $15.33B across 365 funding events covering 349 companies. Both event counts and funding amounts exceeded Q2 2026 and Q3 2024 and 2025. Early-stage funding also improved from Q3 2025, although amounts remained below Q3 2024. Large debt and refinancing transactions contributed significantly to the overall funding total. Please note: In this report, funding

Bio/pharma IPO activity increased in Q3 2026, with BPIQ recording 10 priced offerings, compared with seven in Q1 and eight in Q2. July brought three listings, August five, and September two. That puts 2026 at 25 IPOs through September, already above the full-year total for each year from 2022 through 2025. The Quarterly View Q3 was the busiest quarter since 2021 in BPIQ’s dataset. Still, its 10 IPOs were well below the 25 recorded in Q3 2021. Activity is recovering, but the m

We've been working with BPIQ AI to provide more information about upcoming catalysts for investors to consider in their diligence of smid-cap biopharma companies. For October and November 2026, BPIQ AI estimated the probability (FN1) that each of 20 Phase 2 and Phase 3 readouts will read out as a clean positive, a clean negative, or with mixed data, along with the potential stock move for each outcome. In this free post, we reveal one of them: the readout BPIQ AI likes least.

ADCs offer a compelling prospect: deliver a potent cancer drug to tumors with greater precision, then turn that approach into meaningful patient benefit. Enhertu has shown what that can look like. It improved survival in HER2-positive metastatic breast cancer and has since expanded into earlier treatment settings. It was also the only ADC in the top 10 oncology drugs by sales for 2025 and H1 2026. For bio/pharma investors, the question is which programs have the evidence to f

We reveal VRDN as one of September’s three hedge fund stock picks. Its TED trials are behind it, while launch execution and a follow-on filing lie ahead.

Explore BPIQ-AI forecasts for September 2026 Phase 2 and Phase 3 readouts, including Clean+, Mixed, and Clean− probabilities, expected stock move ranges, and insights from live options data.

Summary Hedge fund holdings can help you discover new investment ideas We identified & follow the top biopharma-focused hedge funds Q2 hedge fund holdings reports were released on ~08/14/26 This report focuses on top holdings of top biopharma hedge funds as of 06/30/26 Top Biopharma Hedge Funds At BPIQ we identified the top smid-cap biopharma-focused hedge funds ^1. We updated our database of holding and other info re: these funds with their recently-released data for holdings

Explore BPIQ’s August 2026 hedge fund stock picks, featuring $MIRM and two more biopharma names with key catalysts ahead.

10 Hot Bio/Pharma Stocks on BPIQ’s Q2 Earnings Radar

Explore hedge fund positions and BPIQ model-portfolio overlap in Terns, Centessa, and RAPT before their 2026 biotech M&A deals.

Three hedge fund-backed biopharma picks. One revealed. See why COGT stands out ahead of two FDA decisions, then unlock the other two July 2026 picks.

The bio/pharma IPO market reopened in H1 2026, as we predicted based on the bullish public bio/pharma market starting in the 2nd half of 2025. However, the bio/pharma IPO activity remains far below its historical peak in 2020/2021. BPIQ recorded 15 IPOs in H1 2026, up 114% from seven in H1 2025. This was the highest first-half total since 2021, but only narrowly above the 14 IPOs recorded in H1 2022 and still far below the 61 recorded in H1 2021. Quarterly Activity Shows a Gr

H1 2026 private bio/pharma funding reached its highest total amount invested of the past three years, but the number of funding events declined by almost 33%. Total capital increased slightly compared with H1 2024 and H1 2025, while funding activity remained well below prior-year levels. This points to an investment environment where capital is still available, but fewer companies are securing it. In total, private companies raised approximately $20.3B across 366 funding even

BPIQ has released its H2 2026 Big Movers list, highlighting biotech catalysts with the greatest potential to drive meaningful stock moves. The list includes 18 Big Movers and 79 Suspected Movers. Suspected Movers are catalysts BPIQ identifies as having significant stock-move potential. Big Movers are near-term Suspected Movers where options-implied volatility confirms that the market is pricing in a large move. Elite and APEX subscribers can also see whether a Big Mover is de

Summary Since 2023, BPIQ model portfolios built around biopharma hedge fund consensus holdings have consistently and significantly outperformed the biotech benchmarks XBI and IBB. Want access to our portfolio holdings and other portfolios' info/tools to help you make better biopharma investment decisions? Sign up for Elite or APEX today? Background After extensive back-testing to identify effective strategies for using the consensus holdings of leading institutional investors

BPIQ’s June 2026 Hedge Fund Stock Picks highlight three biopharma catalyst setups. This free version features CLDX, a later-stage immunology pick with pivotal data ahead.

ASCO 2026 was not only about individual readouts. Across five days, the meeting showed where oncology innovation is moving next: more targeted, more biomarker-driven, and increasingly built around complex therapeutic platforms. From BPIQ’s lens, several technology themes stood out. ADCs Stayed at the Center of Oncology Antibody-drug conjugates remained one of the most active modalities across the meeting. Nectin-4 was especially visible, with Corbus, Eli Lilly, and Bicycle Th

ASCO 2026 delivered important updates across hematologic malignancies, lung cancer, breast cancer, gastrointestinal cancers, melanoma, and several rare and difficult-to-treat tumors. Across the meeting, ADCs, bispecific antibodies, cell therapies, radioligand approaches, and increasingly precise biomarker-driven strategies remained at the center of oncology innovation. One presentation stood above the rest. During the Day 3 Plenary Session, Revolution Medicines presented what

Summary Since 2023, BPIQ model portfolios built around biopharma hedge fund consensus holdings have consistently and significantly outperformed the biotech benchmarks XBI and IBB. Want access to our portfolio holdings and other portfolios' info/tools to help you make better biopharma investment decisions? Sign up for Elite or APEX today? Background After extensive back-testing to find to identify the best strategies for using consensus holdings of top institutional investors

ASCO 2026 continued to deliver important clinical updates on Day 2, with presentations spanning cell therapy, lung cancer, breast cancer, gastrointestinal tumors, and rare diseases. While ADCs remained an important part of the meeting, Day 2 highlighted growing momentum behind engineered cell therapies, precision oncology approaches, and several late-stage studies that could influence future standards of care. Cell Therapy Continues Expanding Beyond Hematology Immatics ($IMTX